pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
Endpoints·Jun 20·1 min read
save

Weekly roundup highlights LGBTQ+ leadership in biopharma and reports of a Novo Nordisk hack

Jun 20, 2026·read at Endpoints ↗Neutral

The latest Endpoints Weekly newsletter was published on June 20, 2026, coinciding with the summer solstice in the northern hemisphere.

The issue spotlights the growing visibility of LGBTQ+ leaders within the biopharma sector, highlighting their contributions and the industry's evolving inclusivity.

It also raises concerns about a potential cyber intrusion at Novo Nordisk, prompting readers to watch for further developments.

source

This writeup was produced by pharmadog from original reporting by Endpoints.

Original headline: “Biopharma’s LGBTQ+ leaders; Novo Nordisk hacked?; and more”

read at Endpoints ↗
84 words · retrieved Jul 2
sharex / twitterlinkedin

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?

companies & drugs in this story

companies
NOVO2Novo Nordisk Inc2

related stories

  • May 18STAT+: Supreme Court rejects challenge to Medicare drug price negotiationSTAT
  • May 13Lilly data point to ‘maintenance’ strategies for GLP-1 weight lossBioPharma Dive
  • May 13STAT+: Pharmalittle: We’re reading about FDA’s Makary resigning, a Lilly weight loss drug trial, and moreSTAT
  • May 12STAT+: Pharmalittle: We’re reading about pharma lobbying, Bristol’s deal with a Chinese partner, and moreSTAT
  • May 12A year after Vertex’s big launch, pain drug research faces a pivotal momentBioPharma Dive